I’m Dr. Peter Salgo, a professor of medicine and anesthesiology at Columbia University College of Physicians and Surgeons; and an associate director of Surgical Intensive Care at New York-Presbyterian Hospital. Heart failure is associated with almost one million hospitalizations annually. Preventing readmissions through evidenced-based medicine is a large part of managing this patient population. As a result, much of their care falls to community physicians. On behalf of MD Magazine, I am excited to introduce an upcoming Peer Exchange focusing on congestive heart failure management. The topics will include: disease state information, understanding the current clinical guidelines, and applying them to hospital discharge planning to ensure a smooth transition of care to the community setting. Current therapeutic options, including the clinical rationale for treatment decision making will also be discussed. The esteemed panel will provide the valuable perspectives of the cardiologist as well as the clinical pharmacist in managing this disease. This video series will become available early 2017. We hope you will find it useful and informative.

Coming Soon; Congestive Heart Failure Peer Exchange



I’m Dr. Peter Salgo, a professor of medicine and anesthesiology at Columbia University College of Physicians and Surgeons; and an associate director of Surgical Intensive Care at New York-Presbyterian Hospital. Heart failure is associated with almost one million hospitalizations annually. Preventing readmissions through evidenced-based medicine is a large part of managing this patient population. As a result, much of their care falls to community physicians. On behalf of MD Magazine, I am excited to introduce an upcoming Peer Exchange focusing on congestive heart failure management. The topics will include: disease state information, understanding the current clinical guidelines, and applying them to hospital discharge planning to ensure a smooth transition of care to the community setting. Current therapeutic options, including the clinical rationale for treatment decision making will also be discussed. The esteemed panel will provide the valuable perspectives of the cardiologist as well as the clinical pharmacist in managing this disease. This video series will become available early 2017. We hope you will find it useful and informative.
Episode 1 Coming Soon; Congestive Heart Failure Peer Exchange
Episode 2 The Underappreciated Burden of Heart Failure
Episode 3 Characteristics of Patients with HFrEF
Episode 4 The Usefulness of Measuring BNP Levels in Heart Failure
Episode 5 Heart Failure Pathways and the Role of Beta Blockers
Episode 6 Blocking the RAAS Pathway in Heart Failure
Episode 7 The Role of Ivabradine in Heart Failure Management
Episode 8 Angiotensin Receptor Neprilysin Inhibition in Heart Failure
Episode 9 The Role of Sacubitril/Valsartan in HFrEF
Episode 10 Acute Decompensated Heart Failure Hospitalization
Episode 11 Hospital Pharmacy Perspective: HF Medication Review

Latest Peer Exchange

Hospital Pharmacy Perspective: HF Medication Review
Hospital Pharmacy Perspective: HF Medication Review
Acute Decompensated Heart Failure Hospitalization
Acute Decompensated Heart Failure Hospitalization
The Role of Sacubitril/Valsartan in HFrEF
The Role of Sacubitril/Valsartan in HFrEF
Angiotensin Receptor Neprilysin Inhibition in Heart Failure
Angiotensin Receptor Neprilysin Inhibition in Heart Failure
The Role of Ivabradine in Heart Failure Management
The Role of Ivabradine in Heart Failure Management
Blocking the RAAS Pathway in Heart Failure
Blocking the RAAS Pathway in Heart Failure
Heart Failure Pathways and the Role of Beta Blockers
Heart Failure Pathways and the Role of Beta Blockers
The Usefulness of Measuring BNP Levels in Heart Failure
The Usefulness of Measuring BNP Levels in Heart Failure
Characteristics of Patients with HFrEF
Characteristics of Patients with HFrEF
The Underappreciated Burden of Heart Failure
The Underappreciated Burden of Heart Failure
Type 2 Diabetes: Improving Care in the Community
Type 2 Diabetes: Improving Care in the Community
Differentiating Among Newer Combinations in Diabetes
Differentiating Among Newer Combinations in Diabetes
Switching to an Insulin-Based Combination
Switching to an Insulin-Based Combination
LixiLan Trials in Type 2 Diabetes
LixiLan Trials in Type 2 Diabetes
GLP-1 Receptor Antagonist Therapy in Type 2 Diabetes
GLP-1 Receptor Antagonist Therapy in Type 2 Diabetes

Most Popular

@MDMagazine

$vAR$